两种抗肿瘤中成药在中晚期胃癌化疗中应用的药物经济学分析

目的研究两种抗肿瘤中成药在中晚期胃癌化疗中的临床作用特点和经济学效果。方法采用回溯法筛选73例晚期胃癌化疗病例，分成A、B两组，A组为金蒲胶囊加化疗组（38例），B组为珍香胶囊加化疗组（35例）。运用药物的疗效比较和药物经济学的成本一效果分析方法进行研究。结果两组患者疗效间差异均无统计学意义（P〉0．05）；两组患者化疗后白细胞、神经毒性、卡氏评分间差异无统计学意义（P〉0．05）；两组患者总成本间差异有统计学意义（P〈0．05）；B组比A组的成本效果比（C／E）明显高。结论A组疗效最具经济学意义。

Pharmacoeconomic Analysis of Two Chinese Patent Antitumor Drugs for Treatment of Stomach Cancer in Combination with Chemotherapy

Objective To explore the clinical evaluation and the cost-effectiveness of two chinese patent antitumor drug for the treatment of advanced stomach cancer. Methods A total of 73 patients with advanced stomach cancer were randomly divided into two groups. In addition to chemotherapy, Group A （ n = 38 ） and B were administered Jinpu capsules and Zhenxiang capsules, respectively. The two groups were pharmacoeconomieally assessed. Results No significant difference in clinical effects was found between the two groups （ P 〉 0.05 ）, and there were not significant differences in abnormal white cells, neurotoxieity and increase in kamofsky performance status （KPS） between the two groups （ P 〉 0.05 ）. There was significant difference in total costs between the two groups （ P 〈 0.05 ） , i.e. the ratio of cost/effectiveness was higher in Group B than in Group A. Conclusion Jinpu capsules is better than Zhenxiang capsules in cost-effectiveness.